GMGunter von Minckwitz

Gunter von Minckwitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gunter von Minckwitz has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

    by Sibylle Loibl, Michael Untch, Nicole Burchardi, Jens Bodo Huober, Jens Uwe Blohmer, Eva-Maria Grischke, Jenny Furlanetto, Hans Tesch, Claus Hanusch, Mahdi Rezai, et al.

    3062 Background: Adding an anti-PD-L1 checkpoint inhibitor durvalumab to standard chemotherapy (CT) may increase pathological complete response (pCR) in patients (pts) with TNBC. Methods: GeparNuevo randomizes pts to durvalumab (D) 1.5 g i.v. or placebo (pl) every 4 weeks (wks). D/pl monotherapy (0.75 g i.v.) is given for the first 2 wks (window phase), followed by a biopsy and D/pl plus nab-paclitaxel (nP) 125 mg/m² weekly for 12 wks, followed by D/pl plus epirubicin/cyclophosphamide (EC) q2 wks for 4 cycles. Randomization is stratified by stromal TILs (sTILs) (low (≤10%), intermediate (11-59%), high (≥60%)). Pts with primary cT1b-cT4a-d disease, centrally confirmed TNBC, and sTILs status can be included. Primary objective compares pCR (ypT0 ypN0) rates. Secondary objectives are pCR rates in stratified subpopulations and according to other pCR definitions; response rates; breast conservation rate; toxicity; compliance and survival. Change in sTILs, Ki67 and other immune biomarkers before CT, after the window phase and after CT will be correlated with outcome. The first 10, 20 and 30 pts will be included in safety interim analyses (SIA). Sample size was planned assuming a pCR rate of 48% for pl (nP treated TNBC cohort in GeparSepto) and of 66% for D (as clinically meaningful benefit), requiring 158 pts to show superiority of D (2-sided α = 0.2, 80% power). Assuming a 10% drop-out rate 174 pts will be randomized. Results: Since 6/2016, 50 pts were recruited within 16 sites; data are presented as available until 01/2017. Median age is 49 years; 86% NST and G3 tumors; sTILs categories 40% low, 40% intermediate and 20% high. Blinded SIA was performed. No pt interrupted D/pl, one nP and one EC. Treatment delay was observed in 9 pts (20.0%) in D/pl, 18 (41.9%) in nP and 2 (13.3%) in EC; dose was reduced in 10 pts (23.3%) in nP and in 4 (26.7%) in EC. 10 pts (20%) had at least one grade 3-4 AE: 4 haematological and 6 non-haematological AEs. 4 SAEs and 5 immune related AEs were reported. 2 pts discontinued study treatment prematurely in the EC phase. Conclusions: The addition of D to standard nP-EC is feasible and does not result in an increased toxicity. Clinical trial information: NCT02685059.


  • A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting.

    by Sibylle Loibl, Jana Barinoff, Sabine Seiler, Thomas Decker, Carsten Denkert, Kristina Luebbe, Jenny Furlanetto, Volkmar Mueller, Christoph Mundhenke, Marcus Schmidt, et al.

    TPS1115 Background: Although endocrine based therapy is recommended as first-line treatment in metastatic breast cancer (MBC) in patients with an HER2-/HR+ tumour up to 50% of the patients receive chemotherapy. Palbociclib (P) a CDK4/6 inhibitor improves PFS by 42% in endocrine sensitive and resistant HER2-/HR+ MBC when added to an endocrine therapy (ET). Patients included in clinical trials are often criticised not to be representative for real world breast cancer patients. Methods: Patients with first-line HER2-/HR+ MBC who are candidate for mono-chemotherapy will be eligible to be randomised 1:1 to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or without maintenance ET. In both study arms, treatment will be given until disease progression, unacceptable toxicity, withdrawal of consent of the patient or change of initial treatment plan (either planned six chemotherapy cycles followed by maintenance ET or chemotherapy until disease progression). Primary objective is to compare the time-to-treatment failure (TTF), defined as time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity and death. Secondary objectives are progression free survival, overall survival at 36 months, amongst other time to event endpoints; investigator assessed overall clinical response; toxicity and compliance; patient well-being and health care utilization by daily monitoring treatment impact. Aim: 360 patients will be accrued to show an improved TTF for P in combination with ET. Recruitment will start in QII/2017 and is planned for approximately 18 months in 100 sites in Germany, Spain, Poland, Italy, France, UK and Canada. Conclusions: The aim of the trial is to demonstrate that an endocrine based strategy consisting of ET plus P is superior to a chemotherapy based strategy as first-line therapy in women with HER2-/HR+ breast cancer in a real world setting.

  • Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).

    by Jenny Furlanetto, Christian Thode, Martina Bassy, Carsten Denkert, Claus Hanusch, Jens Bodo Huober, Christian Jackisch, Sherko Kummel, Andreas Schneeweiss, Michael Untch, et al.

    10068 Background: Women ≤45 years (yrs) treated with chemotherapy (CT) for EBC have a high risk of developing CIOF. Awareness of CIOF is essential for young women. Methods: 740 patients (pts) aged ≤45yrs treated with anthracycline or taxane-based CT for EBC from 4 German neoadjuvant/adjuvant trials were included. Blood samples were collected at baseline (N=740), end of treatment (EOT n=740), 6 (n=177), 12 (n=113), 18 (n=69), 24 (n=47) months (m) after EOT. Only samples collected in a time sequence were included. Estradiol (E2), Follicle-Stimulating Hormone (FSH) and Anti-Müllerian Hormone (AMH) were centrally assessed. CIOF was defined as FSH >12.4IU/l and E2


  • Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial.

    by Sherko Kummel, Johannes Holtschmidt, Bernd Gerber, Albert Von der Assen, Joerg Heil, Marc Thill, David Krug, Christian Schem, Carsten Denkert, Juliane Lubitz, et al.

    555 Background: It is not clear whether SLNB performed with LSG is necessary to reliably detect sentinel lymph nodes (SLN) in breast cancer. The omission of LSG might offer an accelerated preoperative workflow, cost reduction, and the opportunity for developing innovative, safe detection strategies. Methods: Patients with cN0 early breast cancer or extensive/high grade DCIS received standard radiolabeled colloid LSG and SLNB. Patients were randomized 1:1 to either conducting SLNB with the performing surgeon knowing the preoperative LSG pictures and results or without knowledge of the LSG results. Since the false negative rate (FNR) of SLNB correlates with the number of harvested SLN, our primary endpoint was the average number of histologically detected SLN per patient in both treatment arms in a non-inferiority design. An average number of 2.7 SLN with a standard deviation of 1.8 was assumed. LSG of all patients were collected postoperatively for central review. Results: Between May 2014 and October 2015 n = 1198 patients were randomized in 23 participating breast centers. Baseline characteristics were well-balanced between the treatment arms. Modified intention-to-treat analysis (n = 1163) confirmed the omission of LSG. The average number of histologically detected SLN was 2.207 with LSG and 2.258 without. The range for the one-sided 95% CI for the difference between the arms was (-0.18, +infinity), i.e. above the pre-specified non-inferiority margin of -0.27. Secondary endpoints were analyzed to rule out differences in reliable detection of nodal metastases. Rates of nodal positive disease as identified by SLNB (Odds ratio (OR) 1.005, 95%CI (0.759, 1.33), p = 0.972) and rates of completion axillary dissection (OR 0.984, 95% CI (0.567, 1.71), p = 0.954) in the two treatment arms and in specific subgroups showed no statistically significant differences. Conclusions: Our results support the hypothesis that SLNB is equally effective irrespective of the knowledge of preoperative LSG results. We therefore suggest performing SLNB without LSG to accelerate the preoperative workflow, reduce costs, and improve the comfort for the patients. Clinical trial information: NCT02481128.


  • Quality of patient-reported outcome for long-term survival of early breast cancer trials.

    by Gunter Von Minckwitz, Jan Steffen, Serban Dan Costa, Wolfgang Janni, Marc Thill, Volkmar Müller, Tanja Neunhoeffer, Hans Georg Lenhard, Gabriele Feisel, Iris Schrader, et al.

    E18121 Background: Follow up (FU) of long term survival in early breast cancer (BC) trials is highly important as treatment effects might change over time and have to be related to late or chronic toxicities. In countries without access to national cancer registries, collection of long term FU is often an unaccomplishable task due to the logistic and financial burden for study sites and sponsors. Patient-reported outcome (PRO) registries for long term FU, like the one established by the German Breast Group (GBG) (von Minckwitz Eur J Cancer 2012) might be an accomplishable option for data collection. Here, we analyzed the quality of the PRO by validation with data provided by the investigators. Methods: Since 2009 almost 6000 participants of GBG trials joined PRO, consenting for name, address, and unique study identifier to be collected by a trustee who sent pseudonymized questionnaires about basic health status approx. once per year. PRO data of 5417 patients from 18 trials with a total of 396 reported events, including deaths (2.5%) and relapses/2nd malignancies (5%), and with no answer/withdrawal (14%), was sent for validation to 210 sites. Results: We received answers from 67 (32%) sites with feedback on 1161 (21%) patients. Sites confirmed the PRO result in 675 (58%) cases. Sites provided more recent data for 210 (18%) patients (including 43 new events), specified a missing event date for 6 (0.5%) patients, changed the diagnosis for 1 patient (from 2nd malignancy to metastasis), had not data available for 262 (23%) patients, or reported contradictory results for 5 (0.4%) patients (1 under- and 4 over-reported events in PRO). Sites were able to provide information for 157/228 (70%) patients not answering via PRO (reporting 24 new events). Sites giving feedback did not know about 6% (10 of 176) of the events reported by PRO. Conclusions: PRO seems to provide valid as well as additional information on disease-free and overall survival of BC patients at much lower costs and effort. Combination of PRO with focused effort by the site on those patients not answering or reporting incomplete data is a practical and valid approach to obtain FU data.

  • Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.

    by Janning Melanie, Volkmar Müller, Eik Vettorazzi, Miguel Cubas-Cordova, Christine Eulenburg, Christian Schem, Peter A. Fasching, Thomas Karn, Tanja N. Fehm, Thorsten Kühn, et al.

    11505 Background: Appropriate biomarkers to guide selection of patients for treatment with bevacizumab are still urgently needed. In this study, we analyzed serum levels of carbonic anhydrase IX (sCAIX) as potential predictive biomarker in samples from the phase III neoadjuvant GeparQuinto breast cancer trial. Methods: Pre-treatment serum sCAIX levels were determined by Enzyme-linked immunosorbent assay. Correlations between sCAIX levels and pathological complete response (pCR, primary endpoint) and disease-free and overall survival (DFS, OS; secondary endpoints) were assessed with appropriate statistical methods using bootstrapping for robust estimates and internal validation. Results: N = 1189 HER2 negative patients (60% of the study population) of whom 577 received bevacizumab (B) were analyzed. sCAIX levels increased upon addition of 4 cycles bevacizumab to neoadjuvant chemotherapy (NCT) indicating modulation of this biomarker by bevacizumab. When treated with NCT-alone, patients with low sCAIX levels at baseline were less likely to achieve pCR compared to those with higher sCAIX (12.2 % vs. 19.7%, p = 0.02). In patients with low sCAIX levels the addition of bevacizumab to NCT significantly improved the probability to achieve pCR (OR, 2.15; 95%CI, 1.26 to 3.72; p = 0.006 pCR rates: 12.2% for NCT vs. 21.3% for NCT-B), while patients with high sCAIX levels did not benefit from bevacizumab (p = 0.25; test for interaction p = 0.003). DFS was significantly prolonged in patients with higher sCAIX level when they were treated with NCT alone in comparison to NCT-B treated patients (HR, 1.44; 95%CI, 1.05 to 1.99; p = 0.023). For patients with low sCAIX levels DFS was numerically improved with addition of bevacizumab (HR, 0.68; 95%CI, 0.40 to 1.10; p = 0.115, 5-year DFS: 69.5% vs. 80.4%). Conclusions: Depending on sCAIX levels we could identify a patient cohort in primary breast cancer that is potentially undertreated with NCT-alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX as a predictive biomarker for bevacizumab with regards to treatment response. In addition, we showed that bevacizumab is not beneficial in patients with high sCAIX level.


  • PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.

    by Jonas C. S. Bergh, Theodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, Birgitta Wallberg, Tommy Fornander, Brigitte Mlineritsch, Sabine Schmatloch, Christian F. Singer, Guenther G. Steger, et al.

    1002 Background: Standard dosing of chemotherapy (ct) based on body surface area results in marked inter-patient variation in pharmacokinetics, toxicities and efficacy. Methods: 2,017 patients with node-positive or high-risk node-negative breast cancer were randomized (1:1) in 86 centers in Sweden, Austria and Germany between February 2007 and September 2011 to either four cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin (E) 38-120 mg/m 2, start at 90 mg/m 2) and cyclophosphamide (C) 450-1200 mg/m 2, start at 600 mg/m 2) Q2W, followed by four cycles of docetaxel (D) 75-100 mg/m 2, start at 75 mg/m 2) Q2W (three weeks pause between EC and D) (tdd arm) or three cycles of standard 5-Fluorouracil (F) 500 E100 C500 Q3W followed by three cycles of D100 Q3W (control arm). Total treatment duration was the same in the two arms. The primary endpoint was breast cancer relapse-free survival (BCRFS) assessed in the intention to treat population. Secondary endpoints included event-free survival (EFS) and overall survival (OS) (Clinicaltrials.gov NCT00798070). Results: The first event-driven analysis was performed in January 2016. With a median follow-up of 5.3 years, 269 BCRFS events were reported, 118 in the tdd arm and 151 in the control arm (Hazard Ratio (HR) (95% CI) = 0.79 (0.62-1.02), p=0.064 by log-rank test). 5-year BCRFS was 88.7% and 85% respectively. Patients in the tdd arm had significantly better EFS (HR 0.79 (0.63-0.99), p=0.043, 5-year EFS 86,7% vs. 82.1%) and a trend to better OS (HR 0.77 (0.57-1.05), p=0.093, 5-year OS 92.1% vs. 90.2%). No significant interactions were found in predefined subgroups, including patients with hormone receptor positive disease and trastuzumab treated. Five cases of myelodysplastic syndrome / acute myeloid leukemia were reported, 3 in the tdd arm and 2 in the control arm. Conclusions: Tailored dose-dense ct resulted in improvement for all studied efficacy endpoints, being statistically significant for EFS compared with conventional ct in the era of contemporary endocrine therapy and trastuzumab. Toxicity data will be presented at the meeting. Clinical trial information: NCT00798070.


  • Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.

    by Caterina Fontanella, Bianca Lederer, Lucia Del Mastro, Carsten Denkert, Sabino De Placido, Claus Hanusch, Francesco Cognetti, Jens Bodo Huober, Michele De Laurentiis, Christian Jackisch, et al.

    529 Background: At the 2014 ASCO meeting we presented the prognostic STAR score, designed in a dataset of 2,248 pts with low/intermediate grade Lum like BC (HER2-/estrogen receptor [ER]+/G1-2) combining tumor stage (AJCC Cancer Staging 7), progesterone receptor [PR] status, and age at baseline. In this study we included pts with high grade Lum like BC in the neoadjuvant dataset and validated the STAR score in the adjuvant GIM2 trial. Methods: EXPLORATORY COHORT (EC): 3,036 Lum like BC (HER2-/ER+/any grade) pts enrolled in 6 prospective randomized trials and treated with anthracycline-taxane based neoadjuvant therapy. VALIDATION COHORT (VC): 1,610 pts with Lum like BC from the 2x2 factorial randomized GIM2 trial (Del Mastro L, Lancet 2015) investigating dose-dense chemotherapy (CT) and the of addition of 5-FU to epirubicin-cyclophosphamide regimen. All patients received adjuvant endocrine treatment. We used uni/multivariate Cox regression analyses to explore the effect of the score on disease free (DFS) and overall survival (OS). Results: In the EC, multivariate analysis adjusted for CPS+EG score (Mittendorf EA, JCO 2011), CT density, and pCR (ypT0/is ypN0) demonstrated that the STAR score added significant independent information on DFS (p= .007) and OS (p= .002). In the VC, the STAR score added similar prognostic information after adjustment for tumor grade, Ki67 (cut off 20%), and CT density (DFS p< .001; OS p <.001). Multivariate analysis hazard ratios (HR) are shown in the table. Conclusions: The STAR score using stage at diagnosis, PR status and age discriminates Lum like BC with worse prognosis, receiving (neo)adjuvant CT and ET.

  • Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.

    by Carsten Denkert, Karsten Weber, Kristin Krappmann, Jens Bodo Huober, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kummel, Jenny Furlanetto, et al.

    522 Background: Gene expression assays are well-established prognostic tools for planning of adjuvant therapy in luminal breast cancer (BC). In the neoadjuvant setting, pCR is not an optimal prognostic factor in luminal BC, and additional parameters are needed. In this study, we evaluated the gene expression test EndoPredict (EP) performed on residual tumor specimen after NACT for predicting prognosis in patients (pts) with ER+/HER2- BC who did not achieve a pCR and compared its prognostic power with the CPS-EG score. Methods: 428 post-NACT FFPE samples of HR+/HER2- BC from the GeparTrio and -Quattro trials were evaluated for mRNA expression of BIRC5, RBBP8, UBE2C, IL6ST, AZGP1, DHCR7, MGP and STC2 by qRT-PCR. The molecular EP and the clinico-molecular EPclin scores were calculated using predefined algorithms and cutoffs. CPS-EG was determined as previously published (Marmé et al. Eur J Cancer). Uni- and multivariate Cox proportional hazard models were used. Results: 175 (41%) of the 428 pts were EPclin low-risk. The continuous EPclin score was significantly associated with poor DFS (HR 2.16 per score unit; 95% CI 1.86-2.51, p < 0.0001). Using predefined diagnostic cutpoints, EPclin high-risk pts had a significantly reduced DFS (HR 4.22; 2.57-6.92; p < 0.0001) and OS (HR 3.66; 2.00-6.69; p < 0.0001). Increased CPS-EG was also significantly linked to poor DFS (HR 2.95; 2.02-4.33; p < 0.0001) and OS (HR 3.70; 2.29-5.99; p < 0.0001). In a bivariate analysis, in contrast to CPS-EG the EPclin score remained significantly prognostic for reduced DFS (HR 2.09, 1.73-2.53, p < 0.0001) and OS (HR 2.16, 1.72-2.72, p < 0.0001). Conclusions: In this prospectively planned biomarker study we show that the information in the hybrid clinico-molecular EPclin score is also prognostic for DFS and OS after NACT and is superior to the clinical CPS-EG score. This approach can be used to assess prognosis after NACT in the luminal non-pCR patient population, and select patients for post-NACT therapies, e.g. treatment with CDK4/6 inhibitors. An additional prospective validation is planned in the ongoing Penelope trial.

  • A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).

    by Valentina Nekljudova, Sibylle Loibl, Gunter Von Minckwitz, Stefan Gluck, Richard Crane, Huiling Li, Xiaolong Luo

    1031 Background: The FDA and EMA have published guidance for industry on the use of pCR as a surrogate endpoint to support accelerated approval in the neoadjuvant treatment of high-risk, EBC. The CTNeoBC consortium (Cortazar 2014), Berruti (2014) and Korn (2015) each used meta analyses to explore the trial level association between pCR odds ratio and the event hazards ratio but did not reach strong association. There are uncertainties raised in both guidances in determining the magnitude of increase in effect size in pCR that is reasonably likely to predict long term clinical benefit. Methods: We introduce a Cox regression model of the relationship among treatment, event hazard, and time dependent effect of pCR as joint co-variates. The trial level association between treatment and event hazard is derived and then shown to be linked with pCR rates. The methodaccounts for the magnitude of the patient level association, which is likely important in predicting clinical benefit. We apply the method to re-analyze the trial level data from CTNeoBC and derive an empirical relationship as an indirect validation between pCR and long term outcome. Results: For the 8 clinical trials included in the CTNeoBC analysis for trial level association, the predictor based on pCR and patient level association served well under the assumption of perfect surrogate endpoint. The difference away from the perfect surrogate prediction was to follow normal distribution based on Kolmogorov-Smirnov test. For event free survival (EFS), the Student's t test p-value of 0.02 suggested non-zero central location with the mean value of -0.161 (s.e. 0.058). For overall survival (OS), the Student's t test p-value of 0.0032 suggested non-zero central location with the mean value of -0.157 (s.e. 0.0393). The observed hazard ratios fit well with the predicted hazard ratios for both EFS and OS and suggest plausible trial level association with the new predictor. Conclusions: Our model predicts well the correlation between pCR and EFS as well as OS. This should serve as a supporting method to help assessment of positive results of clinical studies in the neoadjuvant setting.